Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 30, 2019 08:00 ET | Source: Passage Bio

Passage Bio Announces Third Gene Therapy Development Program in Krabbe Disease and Supports Million Dreams Fundraising Gala

PHILADELPHIA, May 30, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases,...
May 29, 2019 08:00 ET | Source: Passage Bio

Passage Bio to Present at Jefferies 2019 Healthcare Conference

PHILADELPHIA, May 29, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases,...
March 28, 2019 08:00 ET | Source: Passage Bio

Passage Bio Appoints Saqib Islam to Board of Directors

PHILADELPHIA, March 28, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases,...
March 05, 2019 08:00 ET | Source: Passage Bio

Passage Bio to Present at the Cowen and Company 39th Annual Health Care Conference

PHILADELPHIA, March 05, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases,...
February 14, 2019 08:00 ET | Source: Passage Bio

Passage Bio Launches with $115.5 Million Series A to Develop AAV-Delivered Therapeutics to Treat Rare Monogenic CNS Diseases

PHILADELPHIA, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Passage Bio today debuted with a $115.5 million Series A financing led by OrbiMed Advisors and joined by Frazier Healthcare Partners, Versant...